Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Jordan has been showing signs of growth in recent years.
Customer preferences: Patient preferences in Jordan are similar to those in other countries in the region. Patients are increasingly looking for treatment options that are effective and have minimal side effects. The preference for oral anticoagulants has been increasing due to their ease of use and lower risk of bleeding compared to injectable anticoagulants. Patients also prefer medications that are affordable and covered by insurance.
Trends in the market: The Anti-Coagulants market in Jordan has been growing steadily due to an increase in the prevalence of cardiovascular diseases and the aging population. The market has been dominated by vitamin K antagonists (VKAs) such as Warfarin. However, in recent years, there has been a shift towards newer oral anticoagulants (NOACs) such as Dabigatran, Rivaroxaban, and Apixaban. This shift is due to the ease of use and lower risk of bleeding associated with NOACs compared to VKAs. The market for NOACs is expected to continue to grow in the coming years.
Local special circumstances: Jordan has a well-developed healthcare system with access to modern medical technologies and treatments. However, the cost of healthcare can be a barrier for some patients. The government has implemented a national health insurance system to provide affordable healthcare to all citizens. The system covers the cost of many medications, including anticoagulants. This has helped to increase access to anticoagulant therapy for patients in Jordan.
Underlying macroeconomic factors: The Jordanian economy has been growing steadily in recent years, with a focus on economic diversification and attracting foreign investment. The healthcare sector has been identified as a priority sector for investment, with the government implementing policies to encourage private sector investment in healthcare. This has led to the development of modern hospitals and medical facilities in the country, which has helped to increase access to healthcare for the population. The growing economy and focus on healthcare investment are expected to continue to support the growth of the Anti-Coagulants market in Jordan.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
